Breakthrough model holds promise for treating Graves' disease
Animal model first to simulate eye complications of thyroid disorder
Researchers have developed the first animal model simulating the eye complications associated with the thyroid condition Graves' disease, a breakthrough that could pave the way for better treatments, according to a recent study accepted for publication in The Endocrine Society's journal Endocrinology.
Graves' disease is an autoimmune disorder that causes the body to produce antibodies that attack the thyroid gland. The condition causes the thyroid gland to become overactive and produce too much thyroid hormone. If left untreated, it can lead to heart failure or osteoporosis.
Among those who have Graves' disease, more than half develop eye complications, according to the study's lead author, J. Paul Banga, PhD, of King's College London School of Medicine in the United Kingdom. These complications include Graves' orbitopathy, where swelling of tissue behind the eyes causes them to bulge outward. The condition can cause pain and lead to blindness.
"Current treatment options for eye complications associated with Graves' disease are limited," Banga said. "Better treatments are needed for Graves' orbitopathy to reduce the risks of permanent disfigurement and social stigma. Having an animal model to test preventative treatments could lead to important advances that will ultimately benefit people with Graves' disease."
The condition is currently treated with steroids, which can cause undesirable side effects such as weight gain and osteoporosis.
Although researchers have developed animal models of Graves' disease in the past, these models were challenging to replicate and none were able to simulate the eye problems seen in people with Graves' disease.
To develop the new model, researchers injected mice with small circular, double-stranded DNA molecules called plasmids. Over the course of three months, scientists used electronic pulses to ensure the DNA molecules were absorbed into the cells of each mouse. Mice that underwent this procedure developed eye problems like those seen in human patients who have Graves' disease, while the control group of mice did not develop these complications.
"The new animal model opens the door for scientists to conduct needed mechanistic studies and identify preventative therapies to minimize this painful and debilitating condition," Banga said.
Original publication
"Retrobulbar Inflammation, Adipogenesis and Acute Orbital Congestion in a Preclinical Female Mouse Model of Graves' Orbitopathy Induced by Thyrotropin Receptor Plasmid-in Vivo Electroporation,"; Endocrinology.
Other news from the department science
Most read news
More news from our other portals
Last viewed contents
Many of the deadliest cancers receive the least amount of research funding - 'Embarrassing' or stigmatized cancers like lung and liver are underfunded
Fast-tracking T cell therapies with immune-mimicking biomaterials
ThromboGenics Announces that Microplasmin Meets Primary Endpoint in Phase III Trial for Vitreomacular Adhesion - Highly significant trial result (p=0.003) demonstrates the potential of microplasmin in the treatment of retinal disease
Early Prediction of Alzheimer’s Progression in Blood
New marker for Alzheimer's discovered
A nanofiber matrix for healing
Similarity between schizophrenia and dementia discovered for the first time - Max Planck researchers on the trails of Emil Kraepelin
How biofuels from plant fibers could combat global warming
Scientists blueprint bacterial enzyme believed to "stealthily" suppress immune response
Biodiesel made from discarded cardboard boxes - Development of a microorganism that doubles the yield of biodiesel precursor production using genetic scissors and based on the principles of evolution
